Great to have Olympian @chrishoy join our team offsite!His insights on process and ‘marginal gains’ drew a powerful parallel between elite sport and our mission to reimagine drug discovery. Leaving us all inspired and re-energised! 🚀#DrugDiscovery #AIforScience #SirChrisHoy https://t.co/Z2xsuTLJHq ...

Core Insights - XtalPi is expanding its research collaboration with Pfizer to develop a next-generation molecular modeling platform aimed at enhancing drug discovery processes through improved accuracy and speed of AI models [1][3][4] Company Overview - XtalPi Holdings Limited, founded in 2015 by MIT physicists, integrates quantum physics, AI, and robotics to provide innovative R&D solutions across various industries including pharmaceuticals and materials science [5] Collaboration Details - The collaboration will focus on creating more accurate predictive models tailored to Pfizer's proprietary chemical space, enhancing small molecule drug discovery and development [3] - XtalPi will utilize its XFEP platform for parameter customization and Free Energy Perturbation calculations to support Pfizer's drug discovery efforts [3] Technological Advancements - The first-generation XtalPi Force Field (XFF) demonstrated superior performance in predicting small molecule geometry and binding affinity, crucial for drug screening and rational design [2] - The new platform aims to deliver accurate predictive tools with significantly improved throughput, enhancing the efficiency of drug development [1][3]

编辑丨王多鱼 排版丨水成文 生物医学研究是增进人类对健康和疾病的理解、推动药物研发以及提升临床护理水平的基础。 然而，在生物医学实验室中，科研人员往往被复杂的实验方案、庞大的数据库、五花八门的分析工具以及不停更新的海量文献所淹没。生物医学研究日益受到这 些重复且分散的工作流程的制约，让科研人员疲于奔命， 严重减缓了科学发现的速度，限制了科学创新。这凸显了科学界对根本性新方法的迫切需求——一种能 够 有效扩展科学专业知识、简化研究工作流程，并充分释放生物医学研究潜力的全新路径。 2025 年 6 月 2 日， 斯坦福大学 黄柯鑫 、 Serena Zhang 、 王瀚宸 、 屈元昊 、 陆荧洲 等研究人员领衔的团队，联合 Genentech、Arc Institute、 加州大学 旧金山分校及 普林斯顿大学等 多个顶尖研究机构，发布了一款 通用生物医学 AI 智能体 —— Biomni ，该智能体能够自主完成横跨遗传学、基因组学、微生物 学、药理学和临床医学等多个生物医学分支领域的复杂研究任务 。 Biomni 的诞生标志着 AI 在生物医学研究中从"工具使用者"向"自主决策者"的跃迁 。通过将分散的科研资源整 ...

Core Insights - The article discusses the launch of Boltz-2, an open-source biomolecular foundation model developed by MIT and Recursion, which significantly improves the accuracy and speed of predicting molecular binding affinities and structures [1][2][5]. Company and Industry Overview - Boltz-2 is a pioneering model that combines structure and binding affinity prediction, achieving near-physics-based accuracy while being over 1,000 times faster than traditional methods [5][6]. - The model is designed to enhance drug discovery processes by allowing researchers to select promising molecules more effectively, thereby improving the success rates of R&D programs [3][4]. - The open-source nature of Boltz-2, including its training code, enables scientists to customize the model for specific molecules, facilitating broader applications in both academic and commercial settings [2][4]. - Recursion, the TechBio company behind Boltz-2, utilizes advanced machine learning algorithms and operates one of the world's most powerful supercomputers, BioHive-2, to support its mission of decoding biology for improved healthcare outcomes [7][8]. - The development of Boltz-2 involved collaboration between MIT's academic expertise and Recursion's AI capabilities, highlighting the importance of partnerships in advancing biotechnological innovations [3][5].

Corporate Presentation June 5, 2025 Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward ...

Core Viewpoint - Regeneron Pharmaceuticals has successfully bid for the majority of assets of 23andMe Holding Co. in a bankruptcy auction, planning to acquire key business units for $256 million [1][2]. Company Acquisition Details - Regeneron intends to acquire 23andMe's Personal Genome Service, Total Health and Research Services business units, Biobank, and related assets, while 23andMe will become a wholly-owned subsidiary of Regeneron [2]. - The acquisition does not include 23andMe's Lemonaid Health business [2]. - The deal is subject to bankruptcy court approval, regulatory clearances, and other customary closing conditions, with completion expected in Q3 2025 [3]. Strategic Benefits - The acquisition is expected to enhance Regeneron's genetics-based drug discovery efforts by integrating 23andMe's consumer genomic services with its research capabilities [6]. - Regeneron aims to leverage the acquired genetic data to drive drug discovery and development, particularly in areas such as cancer, infectious diseases, and immune disorders [4][6]. Commitment to Privacy - Regeneron has committed to maintaining 23andMe's consumer privacy standards and complying with data protection laws, ensuring transparency regarding the use of customer data [7].